Navigation Links
Fighting cancer - Multiple Myeloma with long-term therapy

A cure for multiple myeloma has not yet been discovered. Currently,its diagnosis means, high-dose chemotherapy followed by repeated //treatments with each relapse of the cancer – a watch and wait approach. Recently, a team of international researchers from France, Switzerland, and Belgium explored the possibility of providing patients with continuous therapy to keep the cancer at bay.Their findings will be published in the November 15, 2006, issue of Blood, the official journal of the American Society of Hematology.

'We have been anxiously waiting for the results of this study in the multiple myeloma community, as the issue of maintenance therapy has never been resolved,' said Joseph Mikhael, MD, a hematologist at the Princess Margaret Hospital in Toronto. 'The results are impressive in favor of ongoing treatment of patients with multiple myeloma, and are quite likely going to change the standard of care.'

In multiple myeloma, an overgrowth of abnormal cells in the bone marrow leads to the painful destruction of bone. In this study, pamidronate, a drug often used early in the treatment of multiple myeloma to help protect against bone damage, was for the first time studied as a maintenance therapy. Its use alone was compared against its combination with, thalidomide, a drug known to inhibit the growth of myeloma cells. A third set of patients in the study did not receive any maintenance therapy, the current standard of care in this disease.

A total of 597 patients participated, and measures of success included the likelihood of the cancer coming back, the risk of an adverse skeletal event (such as a bone lesion), and the patients' overall survival probability. The findings are listed below

(a)The results of using pamidronate alone compared with going without maintenance therapy were similar. The three-year probability of the patients remaining relapse-free was 38 percent without maintenance therapy and only somewha t better – at 39 percent – with pamidronate alone. The addition of thalidomide significantly improved these odds to 51 percent.

(b)The use of pamidronate did not decrease the number of bone events as anticipated, and there was no significant difference in the number of these events between the three treatment groups.

(c)The chance of overall survival four years after study enrollment in the pamidronate-thalidomide group was 87 percent. Patients in the pamidronate-alone arm had a 74 percent survival probability compared with those not receiving therapy at 77 percent. Thalidomide, however, is not for everyone. The drug was originally dosed at 400 mg per day, but after 15 months, the median dose was decreased by half because of drug-related toxicity. Thalidomide was discontinued in 39 percent of the patients due to side effects such as numbness, tingling, or pain in the hands and feet, fatigue, and constipation. In contrast, only 4 percent of patients discontinued pamidronate.

Patients most likely to benefit from the addition of thalidomide to maintenance therapy were those whose responses to the original chemotherapy were not as successful, and those who did not have a chromosome 13 deletion.This chromosomal abnormality is found in about 15-20 percent of patients with multiple myeloma and is associated with a poorer prognosis.

'Thalidomide shows great promise for keeping multiple myeloma in check after chemotherapy,' said Michael Attal, MD, PRD, lead author of the study and Head of the Department of Hematology at H?pital Purpan in Toulouse, France. 'If measures can be taken to mediate the toxicity of the drug, or if only those who would get the most benefit from it are treated, this could be an effective long-term therapy for many patients.'

Source-Eurekalert
AH
'"/>




Related medicine news :

1. The Possibility Of Fighting HIV with Another Virus Questioned
2. Beer Found To Be Effective In Fighting Cardiovascular Disease
3. Fighting against disease as easy as eating eggs
4. New Drug Combination For Fighting Tuberculosis
5. LG To Market Air Conditioner Capable of Fighting Bird Flu
6. Now A Cancer-Fighting Tomato
7. WHO And China Set Up Collaborative Center For Fighting Bird Flu
8. Tata Memorial Centre Wins Global Award For Fighting Cancer
9. Large Scale Free Access On Usage Of HIV Drugs Could Help In Fighting Its Spread
10. A Chewing Gum That Helps in Fighting Tooth Decay
11. Fighting AIDS – a joint venture of the rich and the poor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care Connections, a ... during the 2017 Annual HIMSS Conference & Exhibition in Orlando, Florida, ... and integrating eye care into mainstream healthcare delivery is powered by Secure ...
(Date:2/19/2017)... ... 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made ... reveal any logo with a glitch reveal in just a few clicks of a mouse. ... animation of each preset. Use these presets to add a uniquely animated logo to any ...
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... CA (PRWEB) , ... February 18, 2017 , ... ... paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 ... and so many other applications. Users can pick and choose from hand-crafted ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... on foundational and sustainable systems change designed to further positively impact the health ... Board of Trustees has long considered it our duty to seriously consider releasing ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an ... cycle portfolio and thought leadership at the 2017 ... a category leader award from KLAS. ... discussion focused on how market trends shape the ... particularly a sophisticated, comprehensive Patient Access solution. The ...
(Date:2/19/2017)... SAN FRANCISCO and ORLANDO, Fla. ... (Nasdaq: NKTR ) today announced that positive ... NKTR-214, in patients with renal cell carcinoma (RCC) were ... immuno-stimulatory therapy designed to expand specific cancer-fighting T cells ... tumor micro-environment and increase expression of PD-1 on these ...
(Date:2/18/2017)... -- Research and Markets has announced the addition of the ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
Breaking Medicine Technology: